日本語View as Markdown

Sustained release of bioactive hydrogen by Pd hydride nanoparticles overcomes Alzheimer's disease.

パラジウム水素化物ナノ粒子による持続的水素放出がアルツハイマー病モデルマウスの認知機能障害を改善する

animal study injection / infusion positive

Abstract

Oxidative stress-driven mitochondrial dysfunction is a central feature of Alzheimer's disease (AD) pathology. This study introduces small-sized palladium hydride (PdH) nanoparticles designed to carry a high hydrogen payload and release it continuously within the AD brain, overcoming the limitation of hydrogen's low aqueous solubility. The catalytic hydrogenation property of palladium endows the released hydrogen with strong bio-reductive capacity, enabling self-catalytic scavenging of cytotoxic hydroxyl radicals (·OH). In AD model mice, bio-reductive hydrogen restored mitochondrial function, suppressed amyloid-beta (Aβ) production and aggregation, prevented synaptic and neuronal apoptosis, and enhanced neuronal energy metabolism through oxidative stress elimination and activation of antioxidant signaling pathways. These combined effects led to measurable improvement in cognitive performance, suggesting that nanoparticle-mediated sustained hydrogen delivery represents a promising strategy for addressing AD-related neurodegeneration.

Mechanism

PdH nanoparticles release hydrogen in situ within the AD brain; palladium's catalytic hydrogenation selectively neutralizes hydroxyl radicals, restoring mitochondrial function, inhibiting Aβ aggregation, blocking neuronal apoptosis, and activating antioxidant pathways to improve cognition.

Bibliographic

Authors
Zhang LL, Zhao PL, Yue C, Jin Z, Liu Q, Du X, et al.
Journal
Biomaterials
Year
2019
PMID
30703744
DOI
10.1016/j.biomaterials.2019.01.037

Tags

Disease:アルツハイマー病 Mechanism:アポトーシス抑制 ヒドロキシルラジカル消去 ミトコンドリア Nrf2 経路 酸化ストレス 活性酸素種

Delivery context

Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).

Safety notes

Intravenous hydrogen-saline infusion is a clinic-only route and is not viable for everyday self-administration. For routine hydrogen intake, inhalation is the most practical route, but inhalation carries explosion risk and concentration matters (empirical LFL of 10%; high-concentration 66% / 100% devices are not recommended).

See also:

Other papers on the same disease / condition

Cite as: H2 Papers — PMID 30703744. https://h2-papers.org/en/papers/30703744
Source: PubMed PMID 30703744